AstraZeneca Gears Up to Vaccinate the World Against Covid-19
Among the front-runners racing to deliver a Covid-19 shot, AstraZeneca has the least vaccine experience. But it has promised the world the most doses—more than three billion.
Related Articles
Could Eating Less Help You Live Longer?
Calorie restriction and intermittent fasting both increase longevity in animals, aging experts say. Here’s what that means for you.
The gut microbiome associates with phenotypic manifestations of post-acute COVID-19 syndrome
Current understanding of the heterogeneity of post-acute COVID-19 syndrome (PACS) is limited. Examining the fecal microbiome in subjects with PACS, Su et al. uncover an association…
Spatiotemporally resolved colorectal oncogenesis in mini-colons ex vivo
Nature – Topobiologically complex mini-colons—which enable the faithful in vitro recapitulation of colorectal cancer tumorigenesis and its environmental determinants—offer the…
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review
This scoping review of randomised controlled trials on artificial intelligence (AI) in clinical practice reveals an expanding interest in AI across clinical specialties and locations.…
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes | NEJM
Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No…
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
Nature – Tumour-derived prostaglandin E2, signaling through its receptors EP2 and EP4, is shown to restrain the responses of tumour-infiltrating stem-like TCF1+CD8+ T lymphocytes, and…